Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director · President & CEO | September 07, 2021 | September 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date September 07, 2021 · Filed September 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 991,405 |
Reported balance
After 2021-09-07 transaction · row 1
1 source rowRow 1 · 2021-09-07 · Sale · Disposed 20,000 · Balance 991,405 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.34 to $15.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.34 to $15.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2021 Filed Sep 9, 2021 16:48 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,000 | $15.47 | $309,400.00 |
DisclosureSEC source: 0001209191-21-055304 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991,405 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.34 to $15.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 18:04 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 8,440 | $14.20 | $119,848.00 |
DisclosureSEC source: 0001209191-21-054300 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,405 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 18:14 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 17,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053534 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,845 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 19:46 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 103,000 | $0.00 Strike: $20.59 | $0.00 |
DisclosureSEC source: 0001209191-21-024294 · doc4.xml · derivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Stock · 103,000 shares Expires 2031-03-30 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30, 2021, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 19:46 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024294 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002,511 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:44 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,103 | $17.98 | $55,791.94 |
DisclosureSEC source: 0001209191-21-018644 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,511 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 17:44 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018644 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,614 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 25, 2021 Filed Feb 25, 2021 21:02 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 11,729 | $19.33 | $226,721.57 |
DisclosureSEC source: 0001209191-21-014547 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,614 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 21:02 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014547 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,343 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award. Read SEC document |
| December 30, 2020 Filed Dec 30, 2020 18:12 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 6,078 | $15.30 | $92,993.40 |
DisclosureSEC source: 0001209191-20-065578 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,593 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1). Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 18:41 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,000 | $16.00 | $80,000.00 |
DisclosureSEC source: 0001209191-20-065406 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,671 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 18:41 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065406 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 947,671 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the third of four possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 16:58 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,000 | $14.95 | $74,750.00 |
DisclosureSEC source: 0001209191-20-064450 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,921 Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 20:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 7,500 | $15.29 | $114,675.00 |
DisclosureSEC source: 0001209191-20-063097 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,921 Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:29 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 11,799 | $16.00 | $188,784.00 |
DisclosureSEC source: 0001209191-20-059475 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 941,421 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 17:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,201 | $16.00 | $51,216.00 |
DisclosureSEC source: 0001209191-20-049749 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,220 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 18:20 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,000 | $16.42 | $82,100.00 |
DisclosureSEC source: 0001209191-20-045254 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 956,421 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.25 to $16.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:40 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,000 | $17.11 | $85,550.00 |
DisclosureSEC source: 0001209191-20-040373 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 961,421 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.01 to $17.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 03, 2020 Filed Jun 3, 2020 19:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,300 | $16.01 | $68,843.00 |
DisclosureSEC source: 0001209191-20-034314 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,421 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 19:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 700 | $16.00 | $11,200.00 |
DisclosureSEC source: 0001209191-20-034314 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,721 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Read SEC document |
| May 22, 2020 Filed May 22, 2020 18:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 371 | $16.00 | $5,936.00 |
DisclosureSEC source: 0001209191-20-031860 · doc4.xml · nonDerivative · entry 3 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,421 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Read SEC document |
| May 21, 2020 Filed May 22, 2020 18:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,500 | $16.00 | $56,000.00 |
DisclosureSEC source: 0001209191-20-031860 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,792 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,200 | $16.00 | $19,200.00 |
DisclosureSEC source: 0001209191-20-031860 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,292 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:04 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,929 | $16.00 | $78,864.00 |
DisclosureSEC source: 0001209191-20-029397 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,492 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 21, 2020 Filed Apr 21, 2020 18:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 6,348 | $15.56 | $98,774.88 |
DisclosureSEC source: 0001209191-20-025306 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 981,421 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 18:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025306 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 987,769 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on April 17, 2020. The vested shares represent the total number of remaining shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001209191-20-013095 · doc4.xml · derivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-24 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 24, 2020, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013095 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,769 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 24, 2021, February 24, 2022 and February 24, 2023, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 18:05 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,000 | $16.05 | $160,500.00 |
DisclosureSEC source: 0001209191-20-002076 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917,769 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.64 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 04, 2019 Filed Dec 4, 2019 19:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,699 | $17.05 | $182,417.95 |
DisclosureSEC source: 0001209191-19-059179 · doc4.xml · nonDerivative · entry 3 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,769 F4 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (3), and does not represent a discretionary trade by the Reporting Person. F5 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 19:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059179 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,468 F3 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 19:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,000 | $25.79 | $257,900.00 |
DisclosureSEC source: 0001209191-19-059179 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,468 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.612 to $25.885, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 18:07 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,000 | $20.79 | $103,950.00 |
DisclosureSEC source: 0001209191-19-055321 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,468 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.68 to $20.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 21:17 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,000 | $18.28 | $182,800.00 |
DisclosureSEC source: 0001209191-19-052481 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,468 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.19 to $18.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 17:36 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,000 | $23.26 | $116,300.00 |
DisclosureSEC source: 0001209191-19-048599 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,468 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.12 to $23.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:31 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,000 | $23.27 | $232,700.00 |
DisclosureSEC source: 0001209191-19-044640 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,468 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.06 to $23.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 29, 2019 Filed May 30, 2019 18:18 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,528 | $21.42 | $118,409.76 |
DisclosureSEC source: 0001209191-19-033518 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,468 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| May 28, 2019 Filed May 30, 2019 18:18 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033518 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,996 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on May 28, 2019. The vested shares represent one-third of the total number of shares subject to the award, and the remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 17:31 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0001209191-19-018214 · doc4.xml · derivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 9,792 | $17.04 | $166,855.68 |
DisclosureSEC source: 0001209191-19-016647 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,996 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.85 - $17.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:27 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,000 | $14.99 | $299,800.00 |
DisclosureSEC source: 0001209191-19-007341 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,788 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.88 - $15.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 04, 2019 Filed Jan 4, 2019 16:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001209191-19-001924 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,788 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 15,000 | $13.13 | $196,950.00 |
DisclosureSEC source: 0001209191-19-001924 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,788 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 - $13.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 17:55 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 15,825 | $12.53 | $198,287.25 |
DisclosureSEC source: 0001209191-19-000404 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,788 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.49 - $12.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 16:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 38,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064402 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,613 F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:16 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,000 | $18.17 | $363,400.00 |
DisclosureSEC source: 0001209191-18-061248 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 - $18.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 17:35 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,000 | $18.78 | $375,600.00 |
DisclosureSEC source: 0001209191-18-056972 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.53 - $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:08 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,000 | $23.79 | $475,800.00 |
DisclosureSEC source: 0001209191-18-053762 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.3501 - $24.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,000 | $19.71 | $394,200.00 |
DisclosureSEC source: 0001209191-18-049923 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.30 - $20.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 16:42 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,000 | $20.64 | $412,800.00 |
DisclosureSEC source: 0001209191-18-042466 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 - $20.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.